| First Author | Zhang N | Year | 2017 |
| Journal | Aging Cell | Volume | 16 |
| Issue | 4 | Pages | 847-858 |
| PubMed ID | 28556540 | Mgi Jnum | J:244755 |
| Mgi Id | MGI:5913534 | Doi | 10.1111/acel.12613 |
| Citation | Zhang N, et al. (2017) Sustained NFkappaB inhibition improves insulin sensitivity but is detrimental to muscle health. Aging Cell 16(4):847-858 |
| abstractText | Older adults universally suffer from sarcopenia and approximately 60-70% are diabetic or prediabetic. Nonetheless, the mechanisms underlying these aging-related metabolic disorders are unknown. NFkappaB has been implicated in the pathogenesis of several aging-related pathologies including sarcopenia and type 2 diabetes and has been proposed as a target against them. NFkappaB also is thought to mediate muscle wasting seen with disuse, denervation, and some systemic diseases (e.g., cancer, sepsis). We tested the hypothesis that lifelong inhibition of the classical NFkappaB pathway would protect against aging-related sarcopenia and insulin resistance. Aged mice with muscle-specific overexpression of a super-repressor IkappaBalpha mutant (MISR) were protected from insulin resistance. However, MISR mice were not protected from sarcopenia; to the contrary, these mice had decreases in muscle mass and strength compared to wild-type mice. In MISR mice, NFkappaB suppression also led to an increase in proteasome activity and alterations in several genes and pathways involved in muscle growth and atrophy (e.g., myostatin). We conclude that the mechanism behind aging-induced sarcopenia is NFkappaB independent and differs from muscle wasting due to pathologic conditions. Our findings also indicate that, while suppressing NFkappaB improves insulin sensitivity in aged mice, this transcription factor is important for normal muscle mass maintenance and its sustained inhibition is detrimental to muscle function. |
